June 2008 Oncology News International

Publication
Article

Cover Story

Dr. Kanti Rai, researcher and 'doctor's doctor'

Trial targeting stem cells in advanced breast ca begins

US cancer patients still plagued by undertreated pain

DEPARTMENTS

Focus on Breast Cancer

Breast US finds cancer that mammo misses in at-risk pts

Zoledronic acid ups PFS in younger early-stage pts

Focus on Colon Cancer

Adjuvant bevacizumab/chemo/RT prevents local recurrence in advanced rectal cancer

Elderly metastatic colorectal cancer patients can receive standard regimens with irinotecan

News & Analysis

Everolimus effective in treating metastatic RCC patients

Focus on Hematology

Novel BiTE antibody mediates contact between T cells and cancer cells

Little benefit seen for personalized anti-Id vaccine in non-Hodgkin’s lymphoma

Focus on Prostate Cancer

MRI can monitor the prostate for local progression after ultrasonic ablation

People & Places

Young fashion designer translates cancer fears into fierce frocks

Recent Videos
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content
The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.

Obrixtamig Plus Topotecan Shows Tolerability, Efficacy in Advanced ES-SCLC

Roman Fabbricatore
July 4th 2025
Article

The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer

15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer

Diana Jaber;Natalie K Heater;Surbhi Warrior;Janice Lu, MD, PhD
July 3rd 2025
Article

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Investigators will present detailed results from the phase 3 FORTITUDE-101 trial at a future medical meeting.

Bemarituzumab Regimen Improves Survival in FGFR2b+ Gastric/GEJ Cancer

Russ Conroy
July 3rd 2025
Article

Investigators will present detailed results from the phase 3 FORTITUDE-101 trial at a future medical meeting.

Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

Ariana Pelosci
July 3rd 2025
Article

The EPCORE NHL-1 trial showed a 41% complete response rate with epcoritamab for patients with relapsed/refractory LBCL.